These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21082919)

  • 1. Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.
    Stasi R
    Expert Rev Hematol; 2008 Dec; 1(2):145-52. PubMed ID: 21082919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
    Stasi R; Evangelista ML; Amadori S
    Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis.
    Ahmed HAW; Masoud AT; Han J; Adel Sofy A; Saeed Ahmed A; Abdesattart AT; Drokow EK; Sun K
    Clin Appl Thromb Hemost; 2021; 27():10760296211005555. PubMed ID: 33874785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
    Cook L; Cooper N
    Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
    Lam MS
    J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag for treatment of thrombocytopenia-associated disorders.
    Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
    Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?
    Sallmon H; Gutti RK; Ferrer-Marin F; Liu ZJ; Sola-Visner MC
    J Perinatol; 2010 Dec; 30(12):765-9. PubMed ID: 20410910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
    Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
    Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
    Panzer S
    Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
    Vadhan-Raj S
    Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
    Wang XL; Li AM
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
    Chiou TJ; Chang YF; Wang MC; Kao CW; Lin HY; Chen TY; Hsueh EJ; Lan YJ; Sung YC; Lin SF; Bai LY; Chen CG
    Transl Res; 2015 Dec; 166(6):750-761.e4. PubMed ID: 26477577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.